Prescribers Should Restrict the Use of Non-FDA-Approved Compounded Bioidentical Hormones, Except for Specific Medical Circumstances
The use of compounded bioidentical hormone therapies (cBHTs) — an increasingly popular approach to relieve symptoms of menopause and male hypogonadism — should be limited to the small number of patients who cannot benefit from an FDA-approved hormone therapy product, says a new report from the National Academies of Sciences, Engineering, and Medicine.
More from Science & TechnologyMore posts in Science & Technology »
- Identical Quantum Particles Pass Practicality Test
- Black Microbiologists Push for Visibility Amid a Pandemic
- When coffee makers are demanding a ransom, you know IoT is *******
- Is anyone working with the FreeBoard dashboard creator? Anything I should know?
- Coronavirus Survey Halted After Workers Faced Racial Slurs, Officials Say